House passes pediatric bill
House passes legislation codifying FDA's "pediatric rule" Nov. 19 by unanimous consent. Senate passed same language (S 160/HR 2957) in July following federal court ruling that FDA lacked statutory authority to require drug studies in children (1"The Pink Sheet" July 28, 2003, p. 4). President Bush is expected to sign the bill into law...
You may also be interested in...
Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Enrollment-boosting strategy backed by industry rep at Duke-Margolis meeting as FDA official suggests having sponsors develop study plans for pregnant and lactating women with ‘elements of’ the requirement for pediatric studies.